PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK
Cancer Res. 2009 69 (8): 3256-61

PMID: 19351834 · PMCID: PMC2849653 · DOI:10.1158/0008-5472.CAN-08-4055

MeSH Terms (16)

Carcinoma, Non-Small-Cell Lung Cell Line, Tumor Chromosome Aberrations Cluster Analysis Drug Resistance, Neoplasm Enzyme Activation ErbB Receptors Erlotinib Hydrochloride Gene Deletion Gene Expression Humans Lung Neoplasms Protein Kinase Inhibitors Proto-Oncogene Proteins c-akt PTEN Phosphohydrolase Quinazolines

Connections (1)

This publication is referenced by other Labnodes entities:

Links